We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

STAT3 DECOY in Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00696176
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : July 23, 2015
Information provided by (Responsible Party):
University of Pittsburgh

Brief Summary:

The primary goal of this study is to evaluate the safety of a transcription factor decoy targeting Signal Transducer and Activator of Transcription 3(STAT3) in patients with head and neck cancer. The rationale for targeting STAT3 using this approach is to decrease STAT3-mediated gene regulation. The study has the following scientific objectives:

  1. To assess the safety of a single dose of intratumoral STAT3 decoy.
  2. To estimate the effect of STAT3 decoy therapy on STAT3 activation levels, STAT3-mediated gene expression, and apoptosis in treated tumors.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: STAT 3 DECOY Early Phase 1

Detailed Description:
The decision to proceed with an exploratory IND study to be conducted in a phase 0 setting was based upon the expectation that the trial will involve very limited human exposure to the STAT3 decoy, and as administered, will have no therapeutic or diagnostic intent. Rather, the trial is designed to determine if intratumoral administration of the STAT3 decoy in human head and neck tumors inhibits STAT3 target gene expression. Given the cumulative evidence supporting STAT3 as a therapeutic target in cancer, and the absence of any clinical trial to date using a STAT3 inhibitor, it was felt that there would be utility in a proof of principal study to determine if the STAT3 decoy inhibits the expression of STAT3 target genes in human head and neck cancers. To support the proposed study design, the Grandis lab carried out a kinetic study in a xenograft model of SCCHN. Preliminary results demonstrated that administration of the STAT3 decoy, but not the mutant control decoy, decreased expression of STAT3 target genes (Bcl-xL and/or Cyclin D1) at time points ranging from 1 to 6 hours.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Preliminary Assessment of the Safety and Biological Activity of Intratumoral STAT3 DECOY in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Study Start Date : August 2008
Primary Completion Date : August 2011
Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: A
STAT 3 decoy administration
single administration to a head and neck tumor

Primary Outcome Measures :
  1. Evaluate the safety of a single injection. [ Time Frame: pre and post surgery ]

Secondary Outcome Measures :
  1. Evaluate the biological activity by observing the consequences of STAT3 decoy administration on STAT3 activation and target gene expression in the tumor. [ Time Frame: pre and post surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of head and neck squamous cell carcinoma(primary or recurrent) amenable to surgical resection.
  • ECOG performance status of 0, 1, or 2.
  • Adequate organ function
  • Age greater than or equal to 18 years
  • Written informed consent.
  • Patients with second primary lesions will be eligible for this trial.
  • Negative pregnancy test, nonlactating, and using effective means of contraception if childbearing potential.

Exclusion Criteria:

  • Subjects who fail to meet the above criteria.
  • Subjects who are pregnant.
  • Subjects with an ECOG performance status >2.
  • Subjects with tumors that are too small to biopsy prior to resection and reserve a portion of the resected specimen for research purposes.
  • Subjects who receive neoadjuvant radiotherapy and/or chemotherapy within four week prior to enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00696176

United States, Pennsylvania
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Jennifer Grandis, MD University of Pittsburgh

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00696176     History of Changes
Other Study ID Numbers: 07-022
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: July 23, 2015
Last Verified: September 2012

Keywords provided by University of Pittsburgh:

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site